Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Clinical trial NCT07470203 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07470203
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-03-31
- Primary completion
- 2029-03-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.